Table 1

Antibody response against GD2 after vaccination with increasing doses of GD2L in a GD2L-KLH plus QS-21 vaccine

Patient no. (dose)ELISA with GD2 Reciprocal peak titeraFACS with NMB-7 % positive cells (MFI)bCDC with NMB-7 % cytotoxicitycITLCd
IgMIgGIgMIgG
PostPostPrePostPrePostPooled gangliosideseSarcoma extract0.5 μg GD2
3 μg
1202010 (20)16 (21)11 (6)10 (5)12
2320010 (10)98 (42)11 (6)17 (9)86
34016010 (13)6 (7)11 (5)10 (5)2
4808010 (6)12 (7)10 (5)8 (5)3
5808011 (7)20 (9)10 (5)9 (6)28
61608010 (15)8 (14)10 (6)12 (5)46
10 μg
725608010 (95)38 (205)10 (10)9 (10)70
83204010 (91)15 (119)10 (7)7 (7)40
932016010 (43)53 (113)10 (7)9 (8)98
101603209 (60)13 (72)12 (7)18 (9)0
114032010 (66)21 (65)9 (7)8 (6)0
123208010 (52)73 (150)9 (7)13 (8)10
30 μg
1312808010 (90)92 (352)10 (8)11 (8)67+++++++
14808010 (46)56 (98)10 (6)10 (6)27+++++
1564064010 (61)70 (135)10 (8)37 (11)42++++++++
16f320010 (63)50 (132)10 (8)16 (14)32++++++++
17256016010 (60)88 (287)9 (6)17 (8)45+++++++++
1820010 (71)19 (112)10 (9)9 (8)7
  • a ELISA titers 1:40 and above are consider positive.

  • b mAb 3F8 used as a positive control for FACS and CDC, it showed >90% positive cells and 75% lysis, respectively. MFI, mean fluorescence intensity.

  • c Specific chromium release after immunization minus specific chromium release before immunization.

  • d Only 30-μg dose tested by ITLC. The TLC immune reaction was graded as − (negative), + (weakly positive), ++ (positive) and +++ (strongly positive).

  • e Pooled gangliosides are GD2, GD3, GM2, and GM3.

  • f Patient 16 received only four vaccines.